Natera, Inc. $NTRA Shares Acquired by DNB Asset Management AS

DNB Asset Management AS lifted its position in Natera, Inc. (NASDAQ:NTRA) by 67.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 38,925 shares of the medical research company’s stock after acquiring an additional 15,689 shares during the quarter. DNB Asset Management AS’s holdings in Natera were worth $6,266,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of NTRA. Sound Income Strategies LLC boosted its stake in Natera by 95.7% in the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 110 shares during the period. Quent Capital LLC acquired a new stake in shares of Natera during the 3rd quarter worth approximately $46,000. Hilltop National Bank lifted its holdings in shares of Natera by 59.8% in the 3rd quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock worth $50,000 after purchasing an additional 116 shares during the last quarter. N.E.W. Advisory Services LLC boosted its position in Natera by 256.8% during the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 226 shares during the period. Finally, Blue Trust Inc. grew its stake in Natera by 23.1% during the 3rd quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock worth $69,000 after buying an additional 81 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera

In related news, insider John Fesko sold 3,594 shares of Natera stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $231.02, for a total transaction of $830,285.88. Following the transaction, the insider directly owned 178,081 shares of the company’s stock, valued at $41,140,272.62. The trade was a 1.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Burkes Brophy sold 6,939 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $227.83, for a total transaction of $1,580,912.37. Following the completion of the sale, the chief financial officer directly owned 52,120 shares of the company’s stock, valued at $11,874,499.60. The trade was a 11.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 360,719 shares of company stock worth $84,194,824 over the last 90 days. 5.63% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of recent research reports. Evercore raised their target price on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Barclays increased their price objective on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Stephens boosted their target price on shares of Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Thursday, January 22nd. Finally, Morgan Stanley boosted their price objective on Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $254.47.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Quarterly beat — Natera reported Q4 revenue of $665.5M and GAAP EPS of $0.35, well ahead of street estimates (revenue ~$600.7M, EPS loss consensus). The beat supports near-term growth expectations and underpins the stock’s recent strength. Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Favorable clinical data — New Signatera MRD data presented at ASCO GU highlight potential utility across genitourinary cancers (including bladder preservation), which may expand clinical adoption and long-term revenue for Natera’s oncology franchise. Signatera MRD Data at ASCO GU
• Positive Sentiment: Trial results — Natera reported results from the SINERGY trial, another clinical datapoint that could support commercial adoption of its assays. Natera Announces Results From the SINERGY Trial
• Positive Sentiment: Analyst upgrades/targets — Robert W. Baird raised its price target to $257 (outperform) and Wells Fargo raised its target to $215 (equal weight), signaling some sell-side confidence in upside from current levels. Benzinga – Analyst Price Target Changes
• Neutral Sentiment: Full-year revenue guidance roughly in line with consensus — Management issued FY2026 revenue guidance (roughly $2.6B–$2.7B), which appears consistent with street expectations and reduces upside surprise potential from guidance alone. (See Q4 release for guidance details.) Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst consensus — Aggregated analyst coverage remains constructive (average “Moderate Buy”), which supports medium-term expectations but doesn’t preclude short-term volatility. Analyst Average Rating
• Negative Sentiment: Valuation and fundamentals concerns — Despite the beat, Natera still shows negative net margin and negative return on equity on a GAAP basis; combined with a high market capitalization and a recent run-up toward 52-week highs, investors may be taking profits. MarketBeat Q4 Coverage
• Negative Sentiment: Heavy intraday volume and selling pressure — Trading volume was well above average, consistent with a distribution day where some holders trimmed positions after the company’s strong quarter; that drove the stock lower despite the positives. (See intraday volume and price action for context.)

Natera Trading Down 3.7%

NTRA stock opened at $208.04 on Monday. The firm’s 50-day moving average is $226.52 and its two-hundred day moving average is $204.17. The company has a market capitalization of $28.78 billion, a price-to-earnings ratio of -135.97 and a beta of 1.65. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 16.71%. The business had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same quarter last year, the business earned ($0.41) earnings per share. On average, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.